Biopharmaceutical News and Research

RSS

Creating a value development plan should be at the forefront of biopharmaceutical market

Mitch DeKoven, Director, HEOR, Real-World Evidence Solutions, IMS Health Inc. and Won Chan Lee, Ph.D., Principal, Health Economics and Outcomes Research, IMS Health, Inc. will present Optimizing Strategic Direction with Systematic Value Development at the Pharmaceutical Market Access Pricing and Reimbursement Conference in San Francisco on October 29, 2013.

11 Jul 2013

Soligenix announces personalized medicine collaboration with SciClone

Soligenix, Inc., a clinical stage biopharmaceutical company focused on developing products to treat inflammatory diseases and biodefense countermeasures where there remains an unmet medical need, announced a personalized medicine collaboration with SciClone Pharmaceuticals in the Company's oral mucositis clinical program with SGX942.

8 Jul 2013

ERYTECH reports fast take-off of GRASPA Phase IIb trial in patients with acute myeloid leukemia

ERYTECH, a French biopharmaceutical company that develops innovative treatments for acute leukemia and other oncology indications with unmet medical needs, announces a fast take-off of its Phase IIb study in Acute Myeloid Leukemia.

4 Jul 2013

Imaxio receives FP7 grant to support the development of S. aureus vaccine

Imaxio, a biopharmaceutical company specialized in vaccines, together with its partners from the Jenner Institute at Oxford University, the European Vaccine Initiative and Preclin Biosystems, is pleased to announce today a European Union award of EUR 5.5 million to support the ‘Bellerophon Project’ consortium to develop a vaccine against Staphylococcus aureus (S. aureus).

3 Jul 2013

Sartorius launches new Sartocheck 4 plus Bag tester

Sartorius Stedim Biotech (SSB), a leading international equipment supplier for the pharma and biotech industries, has launched the new Sartocheck 4 plus Bag tester, the latest addition to its well-established Sartocheck line.

From Sartorius 3 Jul 2013

First clinical study for development of SGX203 to treat pediatric Crohn's disease

Soligenix, Inc. (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat inflammatory diseases and biodefense countermeasures where there remains an unmet medical need, announced today that it has enrolled and treated all patients in the Phase 1 Study BDP-PCD-01; the first clinical study for development of SGX203 (oral beclomethasone 17,21-dipropionate or oral BDP) for the treatment of pediatric Crohn's disease.

1 Jul 2013

Hospira receives positive opinion from EMA's CHMP for EC approval of Inflectra

Hospira, the world's leading provider of injectable drugs and infusion technologies, today received a positive opinion from the European Medicines Agency Committee for Medicinal Products for Human Use, recommending the European Commission approval of Inflectra (infliximab) for rheumatoid arthritis, inflammatory bowel disease and plaque psoriasis.

28 Jun 2013

Eleven Biotherapeutics reports positive results from EBI-005 Phase 1b/2a study in patients with DED

Eleven Biotherapeutics, a biopharmaceutical company designing and engineering novel and differentiated protein-based biotherapeutics for ocular diseases, announced today positive topline clinical results from a 6-week randomized, double-masked, placebo-controlled Phase 1b/2a study of EBI-005 in patients with dry eye disease.

28 Jun 2013

Dassault Systèmes launches industry solution experience for pharmaceutical, biotech companies

Dassault Systèmes, the 3DEXPERIENCE Company, a world leader in 3D design, 3D Digital Mock Up and Product Lifecycle Management solutions, announced today the launch of a new industry solution experience for pharmaceutical and biotech companies, "Licensed to Cure for BioPharma."

27 Jun 2013

Sprout Pharmaceuticals resubmits flibanserin NDA for treating HSDD in pre-menopausal women

Sprout Pharmaceuticals, the Raleigh-based pharmaceutical company developing flibanserin, a treatment being evaluated for Hypoactive Sexual Desire Disorder in pre-menopausal women, confirmed today that the company has resubmitted the New Drug Application for flibanserin earlier this year and expects US Food and Drug Agency action before the end of 2013.

27 Jun 2013

Kiadis Pharma to receive innovation credit from AgentschapNL to conduct Phase II study for ATIR

Kiadis Pharma B.V., a clinical stage biopharmaceutical company developing treatments for blood cancers, announced today that it will receive an innovation credit of up to €3 million from AgentschapNL, a division of the Dutch Ministry of Economic Affairs, to support the Phase II clinical development of Kiadis Pharma's lead pipeline product, ATIR™

26 Jun 2013

CytRx reaches targeted enrollment in aldoxorubicin Phase 2b study for treatment of soft tissue sarcoma

CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, announced that it has reached the targeted enrollment of 105 evaluable patients in its international Phase 2b clinical trial with aldoxorubicin as a first-line treatment for soft tissue sarcoma.

25 Jun 2013

Medicago produces Rotavirus VLP vaccine candidate using plant-based manufacturing platform

Medicago Inc. (TSX: MDG; OTCQX: MDCGF), a biopharmaceutical company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced the successful production of a Rotavirus VLP vaccine candidate comprising all four structural antigens of rotavirus (VP2, VP4, VP6 and VP7) using Medicago's plant-based manufacturing platform.

20 Jun 2013

Ambrx, ZMC partner to develop and commercialize ARX788 for treatment of Her2-positive breast cancer

Ambrx and Zhejiang Medicine Co. Ltd. today announced that they have formed a collaboration to develop and commercialize ARX788, Ambrx's most advanced internally developed site-specific antibody drug conjugate targeting Her2-positive breast cancer.

17 Jun 2013

NPS Pharmaceuticals president receives Ernst & Young Entrepreneur Award in Life Sciences category

NPS Pharmaceuticals, Inc. (NASDAQ: NPSP), a biopharmaceutical company pioneering and delivering therapies that transform the lives of patients with rare diseases worldwide, today announced that president and chief executive officer Francois Nader, M.D. has received the Ernst & Young Entrepreneur Of The Year® 2013 Award in the Life Sciences category in New Jersey. Dr. Nader was presented with the award at a special gala event on June 13 at the Hyatt Regency New Brunswick, New Jersey.

15 Jun 2013

NICE Appraisal Committee reconfirms clinical effectiveness of ILUVIEN

Alimera Sciences, Inc., a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that the Appraisal Committee of the United Kingdom's National Institute for Health and Care Excellence has issued a positive Appraisal Consultation Document on ILUVIEN for the treatment of pseudophakic patients with chronic diabetic macular edema considered insufficiently responsive to available therapies.

14 Jun 2013

Perfinity, Thermo Fisher Scientific sign co-marketing agreement for automated online biopharmaceutical analysis system

Perfinity Biosciences Inc. has announced the signing of an agreement with Thermo Fisher Scientific Inc., the world leader in serving science, to co-market an automated protein sample preparation and analysis system.

From Thermo Fisher Scientific Inc. 13 Jun 2013

Medicago gets Health Canada clearance to initiate Phase II clinical trial for H5N1 vaccine

Medicago Inc., a biopharmaceutical company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles, today announced it has received clearance by Health Canada to initiate its Phase II dose-sparing clinical trial for an H5N1 Avian Influenza VLP vaccine candidate ("H5N1 vaccine").

11 Jun 2013

MHN, Auxilium Pharmaceuticals launch new health awareness program on Peyronie's disease

Men's Health Network and Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, have announced the launch of a new health awareness program called "Ask About the Curve" to provide information about Peyronie's disease and to help empower men to have meaningful discussions about their condition with their partner and their healthcare provider.

11 Jun 2013

GE Healthcare plans to invest $2 billion to develop innovative software for healthcare systems

GE Healthcare announced today its plans to invest $2 billion over the next five years to accelerate the development of innovative software for healthcare systems and applications.

11 Jun 2013

Biopharmaceutical News and Research

Creating a value development plan should be at the forefront of biopharmaceutical market

Soligenix announces personalized medicine collaboration with SciClone

ERYTECH reports fast take-off of GRASPA Phase IIb trial in patients with acute myeloid leukemia

Imaxio receives FP7 grant to support the development of S. aureus vaccine

Sartorius launches new Sartocheck 4 plus Bag tester

First clinical study for development of SGX203 to treat pediatric Crohn's disease

Hospira receives positive opinion from EMA's CHMP for EC approval of Inflectra

Eleven Biotherapeutics reports positive results from EBI-005 Phase 1b/2a study in patients with DED

Dassault Systèmes launches industry solution experience for pharmaceutical, biotech companies

Sprout Pharmaceuticals resubmits flibanserin NDA for treating HSDD in pre-menopausal women

Kiadis Pharma to receive innovation credit from AgentschapNL to conduct Phase II study for ATIR

CytRx reaches targeted enrollment in aldoxorubicin Phase 2b study for treatment of soft tissue sarcoma

Medicago produces Rotavirus VLP vaccine candidate using plant-based manufacturing platform

Ambrx, ZMC partner to develop and commercialize ARX788 for treatment of Her2-positive breast cancer

NPS Pharmaceuticals president receives Ernst & Young Entrepreneur Award in Life Sciences category

NICE Appraisal Committee reconfirms clinical effectiveness of ILUVIEN

Perfinity, Thermo Fisher Scientific sign co-marketing agreement for automated online biopharmaceutical analysis system

Medicago gets Health Canada clearance to initiate Phase II clinical trial for H5N1 vaccine

MHN, Auxilium Pharmaceuticals launch new health awareness program on Peyronie's disease

GE Healthcare plans to invest $2 billion to develop innovative software for healthcare systems

How to optimize your cell line development eBook

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News